NYSE:CHRO Chromocell Therapeutics (CHRO) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CHRO Stock Alerts $1.34 -0.08 (-5.63%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$1.34▼$1.4350-Day Range$1.23▼$2.7152-Week Range$1.21▼$6.00Volume18,242 shsAverage Volume16,219 shsMarket Capitalization$7.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsTrends Get Chromocell Therapeutics alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Chromocell TherapeuticsChromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Read More CHRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CHRO Stock News HeadlinesMay 20, 2024 | investorplace.comCHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024May 13, 2024 | globenewswire.comChromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024April 9, 2024 | globenewswire.comChromocell Issues Letter to Stockholders from Chief Executive OfficerMarch 21, 2024 | globenewswire.comChromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon ChandlerMarch 18, 2024 | globenewswire.comChromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023March 11, 2024 | globenewswire.comChromocell to Present at Sidoti Virtual Investor Conference March 13-14February 27, 2024 | globenewswire.comBenuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare SolutionsFebruary 21, 2024 | globenewswire.comChromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 MillionFebruary 16, 2024 | globenewswire.comChromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public OfferingSee More Headlines Receive CHRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chromocell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CHRO CUSIPN/A CIK1919246 Webchromocell.com Phone732-514-2636FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,770,000Free FloatN/AMarket Cap$7.73 million OptionableN/A BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Francis Knuettel II (Age 58)M.B.A., CEO, CFO, Treasurer & Secretary Comp: $107.5kDr. Eric Lang M.D. (Age 61)Chief Medical Officer Comp: $264.99kKey CompetitorsMiNK TherapeuticsNASDAQ:INKTEstrella ImmunopharmaNASDAQ:ESLAPluriNASDAQ:PLURCortexymeNASDAQ:CRTXSAB BiotherapeuticsNASDAQ:SABSView All CompetitorsInstitutional OwnershipAnson Funds Management LPBought 251,888 shares on 5/14/2024Ownership: 4.284%View All Institutional Transactions CHRO Stock Analysis - Frequently Asked Questions How have CHRO shares performed in 2024? Chromocell Therapeutics' stock was trading at $4.80 at the start of the year. Since then, CHRO shares have decreased by 72.1% and is now trading at $1.34. View the best growth stocks for 2024 here. How were Chromocell Therapeutics' earnings last quarter? Chromocell Therapeutics Co. (NYSE:CHRO) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.55) EPS for the quarter. When did Chromocell Therapeutics IPO? Chromocell Therapeutics (CHRO) raised $7 million in an initial public offering (IPO) on Friday, February 16th 2024. The company issued 1,100,000 shares at a price of $6.00 per share. When does Chromocell Therapeutics' lock-up period expire? Chromocell Therapeutics' lock-up period expires on Wednesday, August 14th. Chromocell Therapeutics had issued 1,100,000 shares in its initial public offering on February 16th. The total size of the offering was $6,600,000 based on an initial share price of $6.00. After the expiration of Chromocell Therapeutics' lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are Chromocell Therapeutics' major shareholders? Chromocell Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Anson Funds Management LP (4.28%). How do I buy shares of Chromocell Therapeutics? Shares of CHRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CHRO) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
